RealFeedApp Participants showed motor improvement of more than 30 points
The study showed no serious adverse events and substantial motor improvements in nine participants with moderate-to-advanced Parkinson's disease.
- Field
- gene therapy
- What they did
- XellSmart presented Phase I clinical trial data for its off-the-shelf cell therapy XS411, designed to treat moderate-to-advanced Parkinson's disease. The single-arm study involved nine participants and reported no serious adverse events or dose-limiting toxicities.
- Why it matters
- Participants demonstrated substantial motor improvements, including an average gain of over five hours of good ON time per day and a reduction in symptom severity scores by more than 30 points at six months.
#cell therapy#parkinson's disease#clinical trial#xs411
